10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-IL-5 Reference Antibody (reslizumab)

Catalog # APR11238

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P05113
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG4SP-opti-PS
Calculated MW	15238

Additional Information

Target/Specificity	IL-5
Expression system	CHO

Protein Information

Name	IL5
Function	Homodimeric cytokine expressed predominantly by T-lymphocytes and NK cells that plays an important role in the survival, differentiation, and chemotaxis of eosinophils (PubMed:2653458, PubMed:9010276). Also acts on activated and resting B-cells to induce immunoglobulin production, growth, and differentiation (By similarity). Mechanistically, exerts its biological effects through a receptor composed of IL5RA subunit and the cytokine receptor common subunit beta/CSF2RB (PubMed:1495999, PubMed:22528658). Binding to the receptor leads to activation of various kinases including LYN, SYK and JAK2 and thereby propagates signals through the RAS-MAPK and JAK-STAT5 pathways respectively (PubMed:7613138).
Cellular Location	Secreted.
Tissue Location	Present in peripheral blood mononuclear cells.

Images

Anti-IL-5 Reference Antibody (reslizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.





The purity of Anti-IL-5 Reference Antibody (reslizumab) is 99%, determined by SEC-HPLC.



Immobilized hu-IL-5 His at 2 μg/mL can bind reslizumab, EC50= 0.04132 μg/mL.